|
1
|
Dorfman HD and Czerniak B: Bone cancers.
Cancer. 75(Supp l): 203–210. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jaffe N: Adjuvant chemotherapy in
osteosarcoma: an odyssey of rejection and vindication. Cancer Treat
Res. 152:219–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong C and Hansen MF: Biomarkers in
osteosarcoma. Expert Opin Med Diagn. 3:13–23. 2009. View Article : Google Scholar
|
|
4
|
Martelli AM, Tabellini G, Bressanin D,
Ognibene A, Goto K, Cocco L and Evangelisti C: The emerging
multiple roles of nuclear Akt. Biochim Biophys Acta.
1823:2168–2178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hemmings BA and Restuccia DF: PI3K-PKB/Akt
pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alessi DR and Cohen P: Mechanism of
activation and function of protein kinase B. Curr Opin Genet Dev.
8:55–62. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Radisavljevic Z: AKT as locus of cancer
positive feedback loops and extreme robustness. J Cell Physiol.
228:522–524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee MW, Kim DS, Lee JH, et al: Roles of
AKT1 and AKT2 in non-small cell lung cancer cell survival, growth,
and migration. Cancer Sci. 102:1822–1828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kirkegaard T, Witton CJ, Edwards J, et al:
Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and
prostatic cancer by FISH. Histopathology. 56:203–211. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu X, Sakon M, Nagano H, et al: Akt2
expression correlates with prognosis of human hepatocellular
carcinoma. Oncol Rep. 11:25–32. 2004.PubMed/NCBI
|
|
12
|
Zhang G, Li M, Zhu X, Bai Y and Yang C:
Knockdown of akt sensitizes osteosarcoma cells to apoptosis induced
by Cisplatin treatment. Int J Mol Sci. 12:2994–3005. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen D, Zhang YJ, Zhu KW and Wang WC: A
systematic review of vascular endothelial growth factor expression
as a biomarker of prognosis in patients with osteosarcoma. Tumour
Biol. 34:1895–1899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Busaidy NL, Farooki A, Dowlati A, et al:
Management of metabolic effects associated with anticancer agents
targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919–2928.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng JQ, Godwin AK, Bellacosa A, et al:
AKT2, a putative oncogene encoding a member of a subfamily of
protein-serine/threonine kinases, is amplified in human ovarian
carcinomas. Proc Natl Acad Sci USA. 89:9267–9271. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Roy HK, Olusola BF, Clemens DL, Karolski
WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene
overexpression is an early event during sporadic colon
carcinogenesis. Carcinogenesis. 23:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng JQ, Altomare DA, Klein MA, Lee WC,
Kruh GD, Lissy NA and Testa JR: Transforming activity and
mitosis-related expression of the AKT2 oncogene: evidence
suggesting a link between cell cycle regulation and oncogenesis.
Oncogene. 14:2793–2801. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheppard K, Kinross KM, Solomon B, Pearson
RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in
cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahajan K and Mahajan NP: PI3K-independent
AKT activation in cancers: a treasure trove for novel therapeutics.
J Cell Physiol. 227:3178–3184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hafsi S, Pezzino FM, Candido S, et al:
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance (review). Int J Oncol. 40:639–644. 2012.PubMed/NCBI
|
|
21
|
Toker A: Achieving specificity in Akt
signaling in cancer. Adv Biol Regul. 52:78–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimura T: Acquired radioresistance of
cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat
Res. 52:539–544. 2011.PubMed/NCBI
|
